NGL FINECHEM Financial Statement Analysis
|
||
The Revenues of NGL FINECHEM have increased by 23.08% YoY .
The Earnings Per Share (EPS) of NGL FINECHEM has decreased by -59.05 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
NGL FINECHEM Last 5 Annual Financial Results
[BOM: 524774|NSE : NGLFINE]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹318 Cr | ₹258 Cr | ₹15,168,639 Cr | ₹153 Cr | ₹153 Cr |
Expenses | ₹249 Cr | ₹178 Cr | ₹13,192,719 Cr | ₹121 Cr | ₹121 Cr |
Operating Profit (Excl OI) | ₹68 Cr | ₹80 Cr | ₹1,975,921 Cr | ₹32 Cr | ₹32 Cr |
Other Income | ₹11 Cr | ₹8.02 Cr | ₹305,079 Cr | ₹4.12 Cr | ₹4.12 Cr |
Interest | ₹1.91 Cr | ₹2.20 Cr | ₹262,571 Cr | ₹2.55 Cr | ₹2.55 Cr |
Depreciation | ₹10 Cr | ₹8.33 Cr | ₹811,201 Cr | ₹6.30 Cr | ₹6.30 Cr |
Profit Before Tax | ₹67 Cr | ₹78 Cr | ₹1,207,228 Cr | ₹28 Cr | ₹28 Cr |
Profit After Tax | ₹50 Cr | ₹57 Cr | ₹833,528 Cr | ₹20 Cr | ₹20 Cr |
Consolidated Net Profit | ₹50 Cr | ₹57 Cr | ₹811,693 Cr | ₹20 Cr | ₹20 Cr |
Earnings Per Share (Rs) | ₹33.04 | ₹80.68 | ₹91.58 | ₹13.14 | ₹32.58 |
PAT Margin (%) | 7.37 | 15.72 | 21.99 | 5.50 | 13.14 |
ROE(%) | 9.63 | 27.90 | 44.76 | 8.72 | 21.85 |
ROCE(%) | 11.96 | 33.91 | 53.53 | 11.93 | 25.25 |
Total Debt/Equity(x) | 0.15 | 0.15 | 0.11 | 0.29 | 0.29 |
Key Financials |
||
Market Cap | : | ₹ 1,403.9 Cr |
Revenue (TTM) | : | ₹ 313.1 Cr |
Net Profit(TTM) | : | ₹ 38.3 Cr |
EPS (TTM) | : | ₹ 61.8 |
P/E (TTM) | : | 36.6 |
Industry Peers & Returns | 1W | 1M | 1Y |
NGL FINECHEM | 4.4% | -1.1% | 73.9% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
NGL FINECHEM Revenues
[BOM: 524774|NSE : NGLFINE]
Y-o-Y | 23.08 % |
5 Yr CAGR | 19.99 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹318 Cr | 23.08 | |
Mar2022 | ₹258 Cr | -100.00 | |
Mar2021 | ₹15,168,639 Cr | 9,902,781.29 | |
Mar2020 | ₹153 Cr | 0.00 | |
Mar2019 | ₹153 Cr | - |
NGL FINECHEM Operating Profit
[BOM: 524774|NSE : NGLFINE]
Y-o-Y | -14.87 % |
5 Yr CAGR | 20.55 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹68 Cr | -14.87 | |
Mar2022 | ₹80 Cr | -100.00 | |
Mar2021 | ₹1,975,921 Cr | 6,118,248.35 | |
Mar2020 | ₹32 Cr | 0.00 | |
Mar2019 | ₹32 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -30.82 % |
5 Yr CAGR | 0.47 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 21.48% | -30.82 | |
Mar2022 | 31.05% | 138.30 | |
Mar2021 | 13.03% | -38.19 | |
Mar2020 | 21.08% | 0.00 | |
Mar2019 | 21.08% | - |
NGL FINECHEM Profit After Tax
[BOM: 524774|NSE : NGLFINE]
Y-o-Y | -11.91 % |
5 Yr CAGR | 25.44 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹50 Cr | -11.91 | |
Mar2022 | ₹57 Cr | -99.99 | |
Mar2021 | ₹811,693 Cr | 4,032,756.16 | |
Mar2020 | ₹20 Cr | 0.00 | |
Mar2019 | ₹20 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -53.12 % |
5 Yr CAGR | -13.46 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 7.37 % | -53.12 | |
Mar2022 | 15.72 % | -28.51 | |
Mar2021 | 21.99 % | 299.82 | |
Mar2020 | 5.5 % | -58.14 | |
Mar2019 | 13.14 % | - |
NGL FINECHEM Earnings Per Share (EPS)
[BOM: 524774|NSE : NGLFINE]
Y-o-Y | -59.05 % |
5 Yr CAGR | 0.35 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹33 | -59.05 | |
Mar2022 | ₹81 | -11.90 | |
Mar2021 | ₹92 | 596.96 | |
Mar2020 | ₹13 | -59.67 | |
Mar2019 | ₹33 | - |
NGL FINECHEM Return on Capital Employed (ROCE)
[BOM: 524774|NSE : NGLFINE]
Y-o-Y | -64.73 % |
5 Yr CAGR | -17.04 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 11.96% | -64.73 | |
Mar2022 | 33.91% | -36.65 | |
Mar2021 | 53.53% | 348.70 | |
Mar2020 | 11.93% | -52.75 | |
Mar2019 | 25.25% | - |
NGL FINECHEM Share Price vs Sensex
Current Share Price | : | ₹2,264.4 |
Current MarketCap | : | ₹ 1,403.9 Cr |
Updated EOD on | : | Apr 16,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | 4.4% |
-1.1% |
73.9% |
SENSEX | -2.4% |
-1% |
21.3% |
NGL FINECHEM related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | -1.3% | 6.1% | 62.6% |
S&P BSE MIDSMALLCAP | -1.4% | 4.4% | 63.3% |
S&P BSE HEALTHCARE | -1.8% | 1.4% | 56.4% |
S&P BSE ALLCAP | -1.9% | 1.5% | 38.3% |
You may also like the below Video Courses
FAQ about NGL FINECHEM Financials
How the annual revenues of NGL FINECHEM have changed ?
The Revenues of NGL FINECHEM have increased by 23.08% YoY .
How the Earnings per Share (EPS) of NGL FINECHEM have changed?
The Earnings Per Share (EPS) of NGL FINECHEM has decreased by -59.05 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs